| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Ananda Developments Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0035 |
| 52 Week High | UK£0.0045 |
| 52 Week Low | UK£0.0015 |
| Beta | 0.91 |
| 11 Month Change | 75.00% |
| 3 Month Change | 75.00% |
| 1 Year Change | -22.22% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1FX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -12.5% | -1.2% | 0.9% |
| 1Y | -22.2% | -17.5% | 5.7% |
Return vs Industry: 1FX underperformed the German Pharmaceuticals industry which returned -17.5% over the past year.
Return vs Market: 1FX underperformed the German Market which returned 5.7% over the past year.
Price Volatility
| 1FX volatility | |
|---|---|
| 1FX Average Weekly Movement | 22.4% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1FX's share price has been volatile over the past 3 months.
Volatility Over Time: 1FX's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 8 | Melissa Sturgess | anandadevelopments.com |
Ananda Developments Plc invests in the medicinal and therapeutic cannabis market. It develops cannabinoid-based medicines targeting the treatment of chronic inflammatory pain conditions. The company was incorporated in 2018 and is based in London, the United Kingdom.
Ananda Developments Plc Fundamentals Summary
| 1FX fundamental statistics | |
|---|---|
| Market cap | €17.01m |
| Earnings (TTM) | -€2.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.0x
P/E RatioIs 1FX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1FX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£1.80m |
| Earnings | -UK£1.80m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00063 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1FX perform over the long term?
See historical performance and comparison